Question 1

Which works better for weight loss, Wegovy or Zepbound?

Accepted Answer

On the trial evidence, Zepbound. Wegovy recorded −14.9% / 68 weeks (STEP-1) and Zepbound −20.9% / 72 weeks (SURMOUNT-1), and the head-to-head comparison put Wegovy at −13.7% against Zepbound at −20.2%. A head-to-head is the strongest form of this evidence because both arms run under one protocol — separate trials are not directly comparable however alike they look.

Question 2

Are Wegovy and Zepbound the same drug?

Accepted Answer

No. Wegovy is semaglutide and Zepbound is tirzepatide — different molecules, and they work differently: GLP-1 receptor agonist against Dual GIP / GLP-1 agonist. Results with one do not predict results with the other.

Question 3

Is Wegovy or Zepbound cheaper?

Accepted Answer

On the manufacturers' own cash pricing: Wegovy at $349-$499/mo (NovoCare), Zepbound at $349-$499/mo via LillyDirect. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Question 4

Does either one have better cardiovascular evidence?

Accepted Answer

Wegovy does. Wegovy: MACE −20% (SELECT, 2023). Zepbound: SURPASS-CVOT pending 2027. This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.

Question 5

Which has worse side effects, Wegovy or Zepbound?

Accepted Answer

The most common adverse event reported was Nausea (44%) for Wegovy and Nausea (29%) for Zepbound. ⚠ Rates come from separate trial populations and are not a like-for-like comparison. In practice how fast the dose is escalated affects tolerability at least as much as which drug it is, which is one reason a slower titration is worth asking for.

Question 6

How is each one taken?

Accepted Answer

Wegovy: Once-weekly subq (5-step titration). Zepbound: Once-weekly subq (6-step titration). Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

Question 7

What does a compounded version of each actually cost?

Accepted Answer

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide from $79 a month and tirzepatide from $99 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Question 8

Can I switch from Wegovy to Zepbound?

Accepted Answer

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Question 9

Which one should I ask for?

Accepted Answer

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

Wegovy vs Zepbound: What the Head-to-Head Actually Showed

The verdict

Side-by-side comparison

What each one costs in the compounded market

Frequently asked questions